Table 2.
Survey sample characteristics
| Survey Responses | Total1 | Confirmed Eczema1 | No Eczema1 | Chi-Square or Fisher’s P-Value |
|---|---|---|---|---|
| All participants, n (%) | 200 (100) | 163 (81.5) | 26 (13) | |
| Diagnosis codes, n (%) | ||||
| AD/eczema M111.00 | 116 (58) | 98 (60) | 13 (50) | 0.330 |
| Infantile eczema M112.00 | 30 (15) | 24 (15) | 4 (15) | 0.930 |
| Flexural eczema M113.00 | 16 (8) | 13 (8) | 2 (8) | 0.960 |
| Allergic/intrinsic eczema M114.00 | 3 (2) | 3 (2) | 0 (0) | 0.486 |
| Eczema not otherwise specified M12z100 | 86 (43) | 73 (45) | 9 (34) | 0.331 |
| Mean number (SD) of the five eczema codes listed above | 1.3 (0.5) | 1.3 (0.6) | 1.1 (0.3) | 0.051 |
| Mean number (SD) of 32 likely eczema codes2 | 2.6 (2.9) | 2.8 (3.1) | 1.7 (1.2) | 0.070 |
| Mean number (SD) of 74 possible eczema codes2 | 4.0 (3.8) | 4.1 (3.9) | 3.2 (3.3) | 0.271 |
| Prescription codes | ||||
| Mean number (SD) of prescriptions for any AD-related therapy3 | 16.3 (24.5) | 17.5 (26) | 11.1 (15.0) | 0.226 |
| Mean number (SD) of topical steroid or calcineurin inhibitor prescriptions3 | 9 (15) | 6.6 (8.9) | 6.5 (7.9) | 0.953 |
| Mean number (SD) of AD-related systemic treatment codes3 | 0.4 (5.8) | 0.5 (6.4) | 0 (0) | 0.691 |
| Other | ||||
| Mean number (SD) of exclusionary diagnostic codes4 | 0.4 (1.7) | 0.3 (0.7) | 0.5 (1.6) | 0.281 |
| Total (%) with at least one exclusionary condition4 | 29 (15) | 25 (15.3) | 3 (11.5) | |
| Mean number (SD) of diagnostic procedure (biopsy or patch testing) codes4 | 0 | 0 | 0 | N/A |
| Mean number (SD) of dermatology consultation codes4 | 0.2 (1.1) | 0.3 (1.6) | 0.0 (0.2) | 0.308 |
| Total (%) with at least one dermatology consultation code | 19 (10) | 18 (11) | 1 (4) | |
| History of atopy, n (%)5 | 64 (39) | 56 (41) | 6 (24) | 0.110 |
| Male, n (%) | 100 (50) | 86 (53) | 9 (35) | 0.086 |
Abbreviation: AD, atopic dermatitis; N/A, not applicable; SD, standard deviation.
Columns do not sum to 200 because of missing values (seven unreturned surveys and four returned surveys missing a response to the eczema question).
Includes topical skin preparations, topical steroids, topical calcineurin inhibitors, topical anti-infective treatments, and AD-related systemic treatments (including methotrexate, azathioprine, mycophenolate, cyclosporine, biologics, or phototherapy); see Supplementary Table S2.
Per physician response on survey; defined as a history of other atopic disease (e.g., asthma or allergic rhinitis) for adults or a family history of atopic disease in a first degree relative if aged under 4 years.